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Clusterin/Apolipoprotein J immunoreactivity is associated with white matter damage in cerebral
small vessel diseases
Aim: Brain clusterin is known to be associated with the
amyloid-β deposits in Alzheimer’s disease (AD). We
assessed the distribution of clusterin immunoreactivity in
cerebrovascular disorders, particularly focusing on white
matter changes in small vessel diseases. Methods: Post-
mortem brain tissues from the frontal or temporal lobes of a
total of 70 subjects with various disorders including cer-
ebral autosomal dominant arteriopathy with subcortical
infarcts and leukoencephalopathy (CADASIL), cerebral
amyloid angiopathy (CAA) and AD were examined using
immunohistochemistry and immunofluorescence. We
further used immunogold electron microscopy to study
clusterin immunoreactivity in extracellular deposits in
CADASIL. Results: Immunostaining with clusterin anti-
bodies revealed strong localization in arterioles and capil-
laries, besides cortical neurones. We found that clusterin
immunostaining was significantly increased in the frontal
white matter of CADASIL and pontine autosomal domi-
nant microangiopathy and leukoencephalopathy subjects.
In addition, clusterin immunostaining correlated with
white matter pathology severity scores. Immunostaining
in axons ranged from fine punctate deposits in single axons
to larger confluent areas with numerous swollen axon
bulbs, similar to that observed with known axon damage
markers such as non-phosphorylated neurofilament H and
the amyloid precursor protein. Immunofluorescence and
immunogold electron microscopy experiments showed
that whereas clusterin immunoreactivity was closely asso-
ciated with vascular amyloid-β in CAA, it was lacking
within the granular osmiophilic material immunolabelled
by NOTCH3 extracelluar domain aggregates found in
CADASIL. Conclusions: Our results suggest a wider role for
clusterin associated with white matter damage in addition
to its ability to chaperone proteins for clearance via the
perivascular drainage pathways in several disease states.
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Introduction
Clusterin, also known, as apolipoprotein J, is a highly con-
served 78–80 kDa heterodimeric glycoprotein expressed
in a wide variety of tissues and cells, encoded by a single
copy gene on chromosome 8 in man [1]. This gene
encodes a 449 amino acid precursor polypeptide which is
cleaved to form the mature secreted clusterin protein; a
heterodimeric glycoprotein consisting of two disulphide
linked α- and β subunits which functions to scavenge and
chaperone damaged proteins in the extracellular com-
partment of tissues [1,2]. Other functional variants of
clusterin are generated by alternative splicing of the
mRNA, producing a cytoplasmic variant, which can
translocate to the nucleus and influence cell survival
[1,3]. The apparent ubiquitous presence of clusterin has
the potential for it to be used as a biomarker for health and
in disease.
Genome-wide association studies have identified
clusterin as one of the risk genes associated with Alzhei-
mer’s disease (AD) [4,5]. Previous studies have reported a
correlation between raised clusterin levels in plasma with
rapid clinical progression and disease severity of AD [6,7],
although this association is not consistently confirmed
[8,9]. Studies measuring protein levels in cerebrospinal
fluid (CSF) revealed elevated CSF clusterin in AD cases
compared with controls [10], and a study of non-
demented and mild cognitive impairment patients
revealed increased CSF clusterin was related to amyloid
β-associated brain atrophy [11].
Further to the role in cerebral amyloid angiopathy
(CAA) and AD, clusterin may be involved in pathological
changes in cerebral autosomal dominant arteriopathy
with subcortical infarcts and leukoencephalopathy
(CADASIL), the most common type of hereditary small
vessel disease (SVD), caused by mutations in the NOTCH3
gene [12,13]. CADASIL is pathologically distinguished by
Periodic Acid Schiff-positive cerebral vessels and the pres-
ence of deposits, 0.2–2 μm in size, of granular osmiophilic
material (GOM) within vessel walls [14–16]. Our previous
work demonstrated that NOTCH3 extracellular domain
(N3ECD) accumulates in GOM and that N3ECD-positive
GOM deposits are found in high abundance around blood
vessels of the grey and white matter (WM), and around pial
vessels and the meninges [16,17]. Recent studies showed
that the extracellular domain of mutant NOTCH3 within
GOM deposits may attract other proteins in a ‘snowball
effect’ [12], and a few intriguing proteins enriched within
the vessel walls have been identified in CADASIL [12,13].
Both the latter studies had indicated that clusterin
immunoreactivity was associated with GOM deposits
within the brain microvasculature in CADASIL subjects.
Here, we investigated clusterin protein expression in
post-mortem brain tissue from different dementing disor-
ders including CADASIL, CAA and hereditary stroke disor-
ders. We used different immunocytochemical methods to
examine patterns and quantify clusterin immunostaining
in the frontal lobe with particular focus on cerebral vessels
and WM pathology.
Methods
Subjects
Post-mortem formalin-fixed paraffin-embedded brain
tissue was obtained from a number of sources. While the
majority of the total of 70 cases were from the Newcastle
Brain Tissue Resource (NBTR), and the rest were obtained
from the MRC London Brain Bank for Neurodegenerative
Diseases, the MRC Sudden Death Brain and Tissue Bank,
University of Edinburgh, Neurology Department, Ludwig
Maximilians University, Germany, Department of Neuro-
pathology, University of Hamburg, Germany, and Depart-
ment of Neuropathology, Upsalla University, Sweden. The
cohort included three cognitively normal control groups
and seven different dementing disorders [16,18] including
SVD, CADASIL, hereditary multi-infarct dementia of
Swedish type (Swedish hMID), pontine autosomal
dominant microangiopathy and leukoencephalopathy
(PADMAL), CAA, dementia with Lewy bodies (DLB), and
AD (Table 1).
Dementia diagnoses and neuropathological examina-
tion were performed essentially as described previously
[18]. Briefly, subjects who were part of prospective studies
in Newcastle had undergone extensive and comprehensive
clinical and cognitive assessments, including the Cam-
bridge Examination for Mental Disorders in the Elderly
and Mini-Mental State Exam. The diagnosis of AD was in
accordance with the National Institute of Neurological
and Communicative Disorders and Stroke/Alzheimer’s
Disease. Clinical diagnosis of vascular cognitive impair-
ment (VCI) or VaD was consistent with the proposed Har-
monization Guidelines for VCI [19] and VCD [20]. The
control groups consisted of subjects with no evidence of
dementia as determined by retrospective or prospective
assessment at recruitment by the absence of neurological
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or psychiatric disorder. SVD cases from other centres were
retrospectively assessed according to the criteria for VCI or
dementia we used. Use of brain tissue was approved by the
local research ethics committee 1 of the Newcastle upon
Tyne Hospitals NHS Foundation Trust, the NBTR commit-
tee and the internal review boards of the Institutional or
Departmental brain collections at other sites including
Upsalla (Sweden), Hamburg (Germany) and Munich
(Germany).
Immunohistochemistry (IHC)
Ten micrometre thick tissue sections from the frontal
lobe, approximate Brodmann area 9 (BA9), were immuno-
histochemically stained with two different anti-clusterin
antibodies (dilution 1:200–2000, Ab#69644 and
Ab104652, Abcam, Cambridge, UK). Ten images from the
neocortex and underlying WM were captured using a
Zeiss Axioplan 2 (Zeiss, Oberkochen, Germany) micro-
scope and analysed using Image Pro Plus software
(V.4.0, Media Cybernetics, Silver Spring, MD, USA).The per
cent area of an image covered by the stain was assessed
(per cent area; %A) as an indication of the extent of
clusterin immunostaining. To assess the intensity of the
immunostaining per area (%A) and between sections, we
also determined the integrated optical density as a measure
of the mean immunoreactivity (IR) for each sample. The
Image Pro analysis software assigns an individual IOD
between 0 and 255 grey levels for each stained pixel in the
delineated object, depending on the stained pixel intensity.
All of the individual grey levels are summed for the entire
stained object, and this total sum is divided by the number
of pixels contained within the object, which gives the mean
pixel IOD per object. From these mean IOD’s per object, a
total IOD was determined for all stained objects within an
image or series of images.
Clusterin immunostaining in axons was scored in each
case as follows: 0, no axonal staining; 1, infrequent,
short punctate staining; 2, infrequent staining of indi-
vidual axons; 3, patches of punctate staining with
swollen axonal lengths; 4, tracts of densely stained and
swollen axons but unstained areas still apparent; 5, com-
plete areas of densely stained and swollen axons
(Figure S1). Specificities of all antibodies were verified by
including irrelevant antibodies or rabbit preimmune
serum in incubated sections with antigens of interest.
We also used two different clusterin antibodies, which
gave similar results. Clusterin antibody specificity (anti-
body Ab#69644) was confirmed by immunoblotting of
frozen human brain tissue extracts (Supplemental
methods), where a 38 kDa band representing secreted
clusterin isoforms was detected [2]. In one CADASIL
subject, a second band at approximately 50 kDa repre-
senting the nuclear isoform was detected (Figure S2).
Table 1. Demographics of subjects in the cohort to analyse clusterin immunostaining in vascular and neurodegenerative disorders
Young
controls
Old
controls
95+
Controls SVD CADASIL
Swedish
hMID PADMAL DLB CAA AD
N (total 70) 8 8 5 8 10 4 5 7 7 8
Mean age (years) 57.6 85.8 99.4 83.4 58.5 42.5 50.0 75.4 83.3 76.8
Range (years) 46–65 78–94 95–104 68–96 77–68 30–48 42–59 71–85 77–88 63–87
Gender (M/F) 5/3 2/6 1/4 2/6 7/3 2/2 2/3 4/3 3/4 3/5
Mean age at onset n/a 46.2 33.8 40.8 69.0 74.0 61.5
Duration of disease n/a 12.6 8.8 9.2 6.6 10.3 8.0
Median WM score 2 2.5 2 2 3 2 3 2 3 2
Range 2–3 2–3 2–2.5 1.5–3 2–3 1–2 2–3 1–3 2–3 2–2.5
Mean age of young controls was not different from the CADASIL and PADMAL subjects. The mean age of the old controls was not different from
SVD or CAA subjects. Mean age of Swedish hMID group was different from young controls and CADASIL (P < 0.05) but not from PADMAL. WM
pathology (WM Score) for each case was scored by two people (LJLC an JLT), and the average score was used in the analysis; the median WM
score was significantly different between groups (P = 0.016), where CADASIL, PADMAL and CAA had highest WM scores of 3, followed by the
old controls with median score of 2.5, and the remaining groups had median score of 2; SVD 95+ Controls, young controls, DLB, AD, Swedish
hMID (Kruskal–Wallis H test). The post-mortem interval between death and immersion fixation of tissue ranged from 9 to 96 h. The length of
fixation of tissues prior to paraffin embedding ranged from 1 to 7 months.
95+ Controls, controls aged over 95 years; AD, Alzheimer’s disease; CAA, cerebral amyloid angiopathy; CADASIL, cerebral autosomal dominant
arteriopathy with subcortical infarcts and leukoencephalopathy; DLB, dementia with Lewy bodies; PADMAL, pontine autosomal dominant
arteriopathy microangiopathy and leukoencephalopathy; SVD, small vessel disease; Swedish hMID, hereditary multi-infarct dementia of the
Swedish type.
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Immunofluorescence (IF)
Six micrometre thick formalin-fixed paraffin-embedded
tissue sections were cut from the same frontal lobe blocks
as for IHC, and underwent antigen retrieval before
blocking with 10% normal horse serum/PBS. Antigen
retrieval was performed by immersing sections in boiling
0.01M citrate (pH6) and leaving to rest for 20 min. The
sections were then transferred into deionized water. Sec-
tions were incubated overnight at 4°C with primary anti-
bodies to clusterin, smooth muscle α-actin (clone 1A4,
1:500, DAKO Cytomation, Glostrup, Denmark), anti-
amyloid β 1–40 (Ter40; 1:200 [21]), anti-amyloid β 1–42
(Ter42: 1:200 [21]) and anti-N3ECD (A1-1, 1:10,000
[22]). For co-localization after removal of primary anti-
bodies, the sections were washed in PBS and incubated for
45 min with the following secondary antibodies: goat
anti-mouse IgG conjugated DyLight 488 at 1:200
(product no. 35502; Thermo Scientific, Rockford, IL, USA)
and goat anti-rabbit IgG conjugated DyLight 550 at 1:200
(product no. 84541; Thermo Scientific) or donkey
anti-goat Alexa Fluor 488 (product no. 1084434; Life
Technologies, Grand Island, New York, USA) at 1:500.
Sections were then washed in PBS before DAPI staining
and mounting in Vectashield (Vector Laboratories,
Burlingame, CA, USA). Sections were imaged using a
Leica TCS SP2 upright confocal microscope and
co-localization graphs (cytoflourograms) of antibodies
were produced using Leica Software LCS 2.61 (Leica
Microsystems, Wetzlar, Germany). Co-localization analy-
sis of proteins was performed using the Just Another
Co-localization Plugin (JaCoP) tool in Image J (National
Institutes of Health, Bethesda, Maryland, USA) [23].
WM pathological assessment
Tissue sections from the frontal lobe were stained with
luxol fast blue and cresyl fast violet (LFB/CFV) to deter-
mine WM pathology. A scoring system based on the
methods of Deramecourt et al. [24] was implemented as
follows from a scale of 0 and 3: 0: normal appearance of
WM; 1: slight loosening of WM and/or slightly dilated
perivascular space; 2: loosening of WM with bubbly
appearance and/or dilated perivascular space; and 3:
severe loosening of WM with bubbly appearance and
severe pallor, swollen axons visible [24]. The WM pathol-
ogy for each case was scored by two operators (JT and
LC) and the average score used in the analysis.
Immunogold electron microscopy
Brain tissues from CADASIL patients were sampled from
the neocortex and WM of the temporal lobes and the cer-
ebral meninges, and stained using immunogold staining
procedures as described previously [16]. The non-
osmicated 700 Å thick epoxy-resin sections were etched
with two changes of 3% sodium meta-periodate for
20 min before heating in 0.01 mol/l citrate buffer (pH 6)
at 90°C for 10 min. After blocking with 5% bovine serum
albumin, 5% normal goat serum and 0.1% gelatine in Tris
buffered saline, the grids were incubated for 90 min at
room temperature with anti-N3ECD (A1-1 antibody,
1:4000) or anti-clusterin (Ab69644, 1:200, Abcam) anti-
bodies in buffer [Tris buffered saline (pH 7.4) containing
1% bovine serum albumin and 0.1% Tween-20]. The sec-
tions were rinsed with three changes of buffer before incu-
bation in EM-grade goat anti-rabbit IgG 5-nm gold probes
(1:30; BB International, Madison, WI, USA) for 90 min.
Gold particle enhancement was performed using a Silver
Enhancing Kit for Light and Electron Microscopy (BB
International). Sections were postfixed in 2% buffered
glutaraldehyde and contrasted with uranyl acetate and
lead citrate. Electron microscopy (EM) images were taken
using a Philips 201 transmission electron microscope
coupled to a Gatan multiscan camera, model 791 (Gatan,
Pleasanton, CA, USA).
Statistical analysis
Results were analysed using spss (IBM, V 19.0, IBM Corpo-
ration, Armonk, NY, USA). Where relevant, following
analysis of variance (anova), post hoc analysis was per-
formed using Tukey’s post hoc. Axonal damage scores used
ordinal data and were analysed for between-group effects
using Kruskal–Wallis H test followed by Mann–Whitney U
test post hoc. For axonal staining, disease groups were
compared the respective age-matched controls and the dif-
ferences between the groups tested using Mann–Whitney
U test. Histograms were presented as mean ± 2 SEM, and
values of P < 0.05 were considered significant.
Results
Clusterin immunolocalization in the neocortex
Both clusterin antibodies showed positive immunostaining
in cerebral vessels in different disorders (Figure 1). Some
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Figure 1. Representative images of clusterin immunostaining in the neocortex, WM and blood vessels in different disorders. Case labels
show images for each disorder: A–D, an 81 year-old female with SVD; E–H, a 44 year-old female with CADASIL; I–L, a 45 year-old male with
PADMAL; M–P, an 86 year-old female with CAA; Q–T, an 84 year-old female with AD; U–X, a 75 year-old male with DLB. Columns
represent immunoreactivity in arterioles of the cortex (A, E, I, M, Q and U), neurones and plaques in the cortex (B, F, J, N, R, V), arterioles
in the WM (C, G, K, O, S, W) and capillaries in the WM (D, H, L, P, T, X). Note very distinct arteriolar immunostaining in CADASIL and
PADMAL (G and K). Arrowheads indicate capillaries. Open arrowheads indicate clusterin immunostaining in amyloid plaques. Magnification
bar = 50 μm.
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cortical neurones were intensely immunostained in all the
disorders (Figure 1). Clusterin immunoreactivity was
observed as dense granular deposits associated with corti-
cal arterioles in both CADASIL and CAA subjects (1E and
1M, respectively), and frequently in capillaries of CADASIL
subjects, often as perivascular punctate deposits (cf.
Figure 1E). Clusterin immunostaining was also found in
cortical plaques and perivascular amyloid deposits in CAA
and AD cases (Figure 1N,R). We further observed occa-
sional clusterin immunopositive granular deposits within
walls of pial arteries in SVD, and CAA cases but less fre-
quently in CADASIL and PADMAL. However, upon quanti-
fication, we found no significant differences in clusterin
percent area stained (%A) in the neocortex (Figure 2A,B),
which avoided any amyloid plaques or vascular deposits
and was representative of only neuronal and glial expres-
sion. There was no correlation between neuronal clusterin
immunostaining and Braak or CERAD scores in the AD
subjects (Spearman’s Rho P > 0.05, data not shown).
Clusterin immunolocalization with vascular
pathology and axon damage
In the WM, clusterin immunoreactivity was evident in
astroglia, in swollen and damaged axons as well as fine
granular or punctate deposits in walls of arterioles and
along many capillaries (Figure 1D,H,L,P). Using Kruskal–
Wallis H tests, we found PADMAL brain tissues to reveal
significantly greater %A of clusterin immunostaining in
the WM (Figure 2A) compared with the other groups, fol-
lowed by Swedish hMID, CADASIL and young control
groups. Clusterin IR was generally not altered across the
different groups (Figure 2B). Upon further examination,
clusterin immunostained multiple cell types in the areas
of WM damage including glia and blood vessels
(Figure 3A,B), as well as swollen and damaged axons
(Figure 3C–E). Axonal immunostaining ranged from fine
punctate deposits in single axons to larger confluent areas
of axon tracts with many swollen axon bulbs, similar to
that observed with known axon damage markers such
as non-phosphorylated neurofilament H (SMI32) and
amyloid precursor protein (not shown) [18]. We developed
a qualitative scoring scale to assess the differences in the
clusterin axon staining in our cases (Figure S1). Kruskal–
Wallis H test revealed significant differences in clusterin
axon score between the groups (P < 0.05), where we found
significant increases in clusterin immunostaining within
damaged axons in CADASIL compared with young con-
trols despite their similar age (P < 0.05, Mann–Whitney U
test) (Figure 3F). However, there were no differences
between young controls and the Swedish hMID and
PADMAL groups (P = 0.847 and 0.408 respectively,
Mann–Whitney U). There was also no significant differ-
ence between the clusterin axon score of the old controls
Figure 2. (A) Percent area (%A) clusterin immunostaining in
frontal grey matter (FGM) and frontal WM (FWM). There was no
significant difference in %A immunostaining in the FGM
(P > 0.05), but CADASIL and PADMAL groups showed significantly
greater %A stain in the FWM (Kruskal–Wallis H test, P = 0.013).
(B) Mean clusterin immunoreactivity derived from IOD (see
Methods) in the FGM and FWM. There was a general lack of
differences in intensity of clusterin immunostaining (P > 0.05).
Error bars are 2 standard errors of the mean.
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and SVD, CAA, and AD (P = 0.178, P = 0.232 and
P = 0.057 respectively, Mann–Whitney U). There was no
correlation between the clusterin axon score and age
across the control groups (P > 0.05, Spearman’s Rho).
Median WM scores and the range of WM scores
showed the following decreasing order in severity:
CADASIL > PADMAL > CAA > old controls > SVD > 95+
controls > young controls > DLB > AD > Swedish hMID
(P < 0.05, Kruskal–Wallis H test, Table 1). Spearman’s rho
correlation revealed a relationship between both clusterin
%A in the WM and WM vascular pathology scores across
the cohort, indicative of a relationship between clusterin
and vascular-type WM damage (Figures 3G,H). To
investigate clusterin immunostaining in dementias with
different primary disease mechanisms (vascular vs.
neurodegenerative degeneration), cases were grouped into
three categories: cognitively normal controls (young con-
trols, old controls and 95+ controls), dementia of vascular
origin (CADASIL, SVD, Swedish hMID, PADMAL and CAA)
or neurodegenerative origin (AD and DLB). We found there
was a trend for a higher median WM score in dementias
with a vascular pathology (VasType) (Kruskal–Wallis H
test, P = 0.059). The %A immunostaining of clusterin
compared in this manner showed no significant difference
between the groups in neocortex. However, the WM had
greater areas of clusterin immunostaining in vascular-
type dementia (Kruskal–Wallis H test, P = 0.02), indicat-
ing an increase in clusterin expression in the presence of
vascular-associated axon pathology and not in cases with
neurodegenerative pathologies where WM was less
affected (data not shown).
Localization of clusterin in CAA and
N3ECD deposits
We used immunofluorescent (IF) labelling to compare
clusterin immunostaining in N3ECD GOM deposits in
CADASIL and amyloid deposits in CAA subjects. IF label-
ling revealed clusterin immunostaining in ring-like depos-
its around vessel walls. These appeared to be larger deposits
than N3ECD deposits, and were localized more in the
adventitial layers rather than tunica media where N3ECD
deposits were observed (Figure 4A and inset, B). Although
we observed positive N3ECD-stained deposits within capil-
lary walls (Figure 4C), clusterin immunostaining was rela-
tively less frequently associated with capillaries. There was
less consistent immunostaining for clusterin in pial blood
vessels or the meninges, despite abundance of N3ECD
labelled GOM in pial arteries (Figure 4D). In contrast,
clusterin was juxtaposed and co-localized with vascular
amyloid-β 1–40 but rarely amyloid-β 1–42 deposits in CAA
(Figure S2). We performed quantitative analysis of the
co-localization of clusterin using image analysis plug-in for
Image J (JaCoP [23]). Co-localization analysis in numerous
CADASIL arterioles revealed that clusterin and N3ECD
immunoreactivities were localized completely indepen-
dently of each other (Figure 5A), where the Manders’ coef-
ficient for fraction of clusterin overlapping N3ECD
was M = 0.017 (P < 0.001), indicating low level of
co-localization. On the contrary, we found clusterin
co-localized strongly with amyloid-β 1–40 in CAA, where
the Manders’ coefficient for fraction of clusterin overlap-
ping amyloid-β 1–40 was M = 0.999 (Figure 5B,
P < 0.001). Clusterin immunostaining was less strongly
associated with amyloid-β 1–42, where many amyloid-β
1–42 deposits were negative for clusterin immuno-
reactivity (Figure 5C). The Manders’ coefficient for the
fraction of clusterin overlapping with amyloid-β 1–42 was
M = 0.59 (P < 0.001). The mean Manders’ coefficients for
the ratio of clusterin to amyloid-β 1–40 (Abeta 40) in CAA
arterioles were significantly higher than Mander’s coeffi-
cients for the ratio of clusterin association with N3ECD
in CADASIL arterioles (Figure 5D, Mann–Whitney U,
P = 0.024).
Ultrastructural localization and distribution
of GOM
To confirm the location of clusterin immunostaining
within CADASIL vessel walls, we performed immunogold
EM with antibodies to N3ECD and clusterin [16].
The N3ECD (A1-1 antibody) demonstrated strong
immunoreactivity within GOM deposits of 0.2–2 μm
diameter (Figure 6A). Clusters of gold particles were only
found on GOM deposits associated with plasma mem-
branes of vascular smooth muscle cells and pericytes
(Figure 6). In contrast, we observed immunoreactivity for
clusterin within the cytoplasm of cells and some
immunostaining within the nucleus of vascular smooth
muscle cells, but there was no evidence of similar positiv-
ity for clusterin within GOM deposits (Figure 6B). This
was in agreement with observations with the high-
resolution confocal microscopy imaging of sections
from CADASIL cases (above). In addition to diffuse
clusterin immunostaining within the adventitial layers of
arterioles, some adventitial cells clearly demonstrated
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Figure 3. (A and B) Typical vascular pathology in a 68 year-old male CADASIL case with p.Arg153Cys NOTCH3 mutation, demonstrating
degeneration of arteriole walls and glial reactivity within the white matter (WM); (A) clusterin immunostaining; (B) LFB/CFV stain. (C and
D) Immunoflourescent labelling of clusterin (arrows) highlights swollen axons in the WM of a 61 year-old male CADASIL case with
p.Arg169Cys mutation (C), and a 63 year-old male AD case (Braak stage VI and CERAD frequent). Colours: clusterin in red, smooth muscle
alpha actin in green and DAPI in blue. Note the absence of green in CADASIL case. (E) Clusterin-stained axonal spherules in WM of a 65
year-old male with CADASIL with p.Arg141Cys NOTCH3 mutation. This case was scored as 5 in axonal clusterin immunostaining scale. (F)
Quantitative scores of axonal staining in all groups as boxplots. *CADASIL different from young controls (YCon, P = 0.040, Mann–Whitney
U test). (G) Scatter graph comparing clusterin percent area (%A) and WM score in all 69 cases, indicating significant positive association
between WM scores and larger areas of clusterin immunostaining [percent area (%A)] (Spearman’s Rho, P = 0.02). (H) Scatter graph
comparing clusterin IR and WM scores in all 69 cases, where there were significant positive association between WM scores and greater
clusterin IR (Spearman’s Rho, P = 0.000). Error bars in F are 2 standard errors of the mean. YCon, Young controls; OCon, old controls; 95+
Con, controls aged over 95 years; SVD, small vessel disease; CADASIL, cerebral autosomal dominant arteriopathy with subcortical infarcts
and leukoencephalopathy; Swedish, hereditary multi-infarct dementia of the Swedish type; PADMAL, pontine autosomal dominant
arteriopathy microangiopathy and leukoencephalopathy; DLB, dementia with Lewy bodies; CAA, cerebral amyloid angiopathy; AD,
Alzheimer’s disease. Magnification bar = 200 μm in A and B, 70um in C, 50um in D and E.
Figure 4. Clusterin and N3ECD immunoreactvities in blood vessels in CADASIL. (A) An image of arteriole from a 44 year-old female
CADASIL subject with p.Arg153Cys NOTCH3 mutation, showing clusterin (green) immunostaining is associated within the adventitial
layers of the blood vessel wall, while N3ECD positive (GOM) deposits (red) are mostly in the tunica media. (B) Higher power image of box in
A. There was no substantial overlap. (C) N3ECD positive deposits or GOM (red) found aggregated within capillary walls, which were negative
for clusterin (green); same CADASIL subject as in A and B. (D) N3ECD positive deposits or GOM (red) in pial arteries and meninges but little
clusterin (green) immunostaining. Image D from a 61 year-old male CADASIL subject with p.Arg169Cys mutation. Scale bar represents
40 μm in A, 20 μm in B, 60 μm in C and 30 μm in D.
NAN 2016; 42: 194–209
202 L. J. L. Craggs et al.
© 2015 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
on behalf of British Neuropathological Society
Figure 5. Co-localization of immunofluorescent labelling of clusterin and aggregated proteins. (A) Clusterin (green) accumulates within
adventitial layers of arterioles in WM, but was not co-localized with N3ECD-labelled GOM (red) in a CADASIL subject with p.Arg153Cys
NOTCH3 mutation. Below A, cytofluorogram of co-localization between clusterin (green, x-axis) and N3ECD (red, y-axis), Manders’
coefficient for fraction of clusterin overlapping with N3ECD was M = 0.017, indicating lack of overlap. (B) Clusterin (green) found to
accumulate in vessel walls of arterioles with amyloid β 1–40 (red) in the cortex of an 88 year-old male with cerebral amyloid angiopathy
(CAA). Below B, cytofluorogram of clusterin (green, x-axis) and amyloid β 1–40 (red, y-axis) with Manders’ coefficient for fraction of
clusterin overlapping amyloid β 1–40 M = 0.999, indicating high overlap. (C) Clusterin (green) observed as aggregates in plaques and
perivascular amyloid deposits. Amyloid β 1–42 was deposited in further deposits, which were negative for clusterin. Same CAA case as in B.
Below C, cytofluorogram of co-localization between clusterin (green, x-axis) and amyloid β 1–42 (red, y-axis), Manders’ coefficient for
fraction of clusterin overlapping amyloid β 1–42 M = 0.59. (D) Mean Manders’ coefficients for the ratio of clusterin to amyloid β 1–40
(Abeta 40) in a CAA case was significantly higher for amyloid β 1–40 compared with clusterin association with N3ECD in a CADASIL case
(Mann–Whitney U, P = 0.024). Magnification bar = 35 μm in A, 20 μm in B and 82 μm in C.
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Figure 6. Immunogold labelling in cerebral vessels by electron microscopy in a 68 year-old male CADASIL patient with p.Arg153Cys
mutation. (A) 5 nm gold particles representing N3ECD immunoreactivity in a white matter arteriole observed only within GOM deposits in
the tunica media (arrows, outlined in box and inset). (B) Immunogold labelling with clusterin antibody revealed positive immunoreactivity
(arrows) in the nucleus, cytoplasm and extracellular compartment of a vascular smooth muscle cell of an arteriole in the white matter of
the same case as A. The GOM (outlined in box and inset) shows lack of positivity for clusterin. (C) Immunofluorescence with confocal
microscopy demonstrating distribution of clusterin (green) and N3ECD (red) antibodies within the wall of a white matter arteriole from the
CADASIL patient with p.Arg153Cys mutation. Clusterin antibody stained diffusely within the outer layers of the vessel wall, as well as
staining within the cytoplasm of cells within the vessel wall. Some positive N3ECD immunoreactivity was observed in close proximity to a
cell with intracellular clusterin immunoreactivity (outlined in box). (D) Higher magnification of boxed area in C. N3ECD immunoreactivity
(red) labelling granular deposits (arrows) surrounding a cell with intracellular clusterin immunoreactivity (green). L, lumen. Magnification
bars = (A and B) 0.5 μm, (inset A and B) 1 μm, (C) 22 μm and (D) 7.5 μm.
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intracellular clusterin immunostaining (Figure 6C,D). As
expected, N3ECD stained small punctate deposits within
the medial layers of the vessel wall, yet there was clearly
some N3ECD punctate immunoreactivity around a cell
with intracellular clusterin immunostaining, suggesting
this cell was an atrophic vascular smooth muscle cell.
Intracellular clusterin immunostaining of vascular cells
was not only observed in CADASIL subjects but was
evident in other disorders (data not shown).
Discussion
Our study showed distinct clusterin immunoreactivity
in cerebral blood vessels in subjects with different
microvascular disorders, including familial early-onset
stroke disorders. Increased clusterin immunoreactivity in
the WM of the frontal lobe was most notable. The expres-
sion of clusterin in the WM was particularly concomitant
with disorders with a vascular component including CAA
and PADMAL, a disease we have previously reported to
show severe vascular pathology in the frontal lobe [18].
Importantly, clusterin immunostaining in our young
control group was of a similar level to some of our
disease groups, and in the case of axonal clusterin
immunoreactivity, our young control group ranked above
DLB, AD and Swedish hMID groups. We have previously
reported on the extent of vascular damage in the brains of
these cases, where we reported >20% of blood vessels in the
FWM of young control cases had arteriolosclerosis equiva-
lent to a disease state [18]. We believe our cohort of
cognitively normal young controls may exhibit some levels
hypoxic damage owing to their comorbidities (lung cancer
cardiovascular disease [18]).These observations are also in
general agreement with previous studies [25–30], which
reported clusterin activation subsequent to different types
of brain injury, specifically the localization in glial cells
within the WM as well as regions of damaged axons.
Increased clusterin immunoreactivity was also related to
WM damage in aged rats [31], and reported to be activated
in astrocytes following middle cerebral artery occlusion in
rats [30]. The lack of significant changes in neuronal
clusterin expression within the neocortex is consistent
with several studies [26,32,33]. Our immunohistochemi-
cal image analysis did not include clusterin imm-
unoreactivity associated with amyloid plaques and
perivascular amyloid in AD and CAA.
Strong clusterin immunoreactivity was evident in both
CAA and AD cases, in which clusterin has been previously
shown to be associated with amyloid plaques and
perivascular amyloid deposits [12,13,33–35]. We also
confirm the localization of clusterin with amyloid-β 1–40
deposits in preference to amyloid-β 1–42 deposits [34].
However, with respect to AD, Zlokovic et al. have shown
that clusterin functions at the blood–brain barrier to clear
amyloid proteins [36] alongside ApoE [37]. It may bind
other proteins due to its flexible structure [38], and is
widely implicated as a biomarker for the diagnosis of AD
[6–8,10,39]. Taking these together, raised plasma and
CSF clusterin levels in patients may be indicative of tissue
damage [40]. However, our observations support the view
that clusterin is an indicator of early-stage WM changes
with multifactorial causes rather than specific for AD. It is
also not unlikely that such accumulation of clusterin
within vessel walls is due to its function as a chaperone
protein during tissue remodelling and disease [2].
In addition to vascular amyloid β 1–40 in CAA, we
found strong clusterin immunostaining within vessel
walls of CADASIL subjects [12,13]. We used high-
resolution confocal microscopy and EM to investigate the
possibility that clusterin may be a component of GOM
deposits. Our results indicate that despite strong
immunostaining for both clusterin and N3ECD-labelled
GOM within the majority of vessel walls, these two anti-
gens were not co-localized within vessel walls. Our obser-
vations suggest the localization of vascular clusterin
occurs as a distinct pathological process different from
GOM formation [12]. It is possible that several disparate
proteins would be identified by mass spectrometry of
extracts of bulk samples of isolated cerebral blood vessels.
We concur with the view that aggregated N3ECD proteins
accumulate as GOM deposits, which then recruit other
proteins in a ‘snowball effect’ so that at the end stage,
there may be numerous proteins within GOM [12].
However, the aggregation of GOM may be limited at the
vascular cell membranes as most deposits are between 0.2
and 2 μm in diameter [16].
Clusterin enrichment in blood vessel walls likely relates
to its function as a chaperone to other proteins, which
may be by-products of ischaemic damage or waste pro-
teins for clearance by the perivascular drainage pathway
[17]. In addition, we observed intracellular expression of
clusterin within vascular smooth muscle cells with
some immunoreactivity within the nucleus. Cytoplasmic
clusterin is thought to be protective against programmed
cell death [1,38], and nuclear clusterin is considered a
pro-cell death isoform [41]. Clusterin expression within
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the walls of arterioles appears common to many cerebral
disorders, and therefore, while GOM may be juxtaposed to
clusterin, our results suggest it is not a specific component
of GOM.
In summary, we have shown high differential clusterin
protein expression in some cerebrovascular disorders
related to dementia. Although not emphasized previously,
we particularly demonstrated that clusterin immuno-
staining was increased during WM damage. Our work does
not support the notion that clusterin is a specific compo-
nent within GOM deposits in CADASIL but it is found to be
strongly associated with amyloid deposits in CAA. Our find-
ings suggest that clusterin plays a role in different vascular-
based disorders, potentially in facilitating clearance of
degraded or aggregated proteins. It is likely that genetic
variation in the clusterin gene affects its ability to clear
proteins at the blood brain barrier and via perivascular
routes.
Acknowledgements
J.L. Taylor was funded by a Newcastle University Faculty
of Medical Sciences summer studentship. We thank Drs
Glyn Nelson, Alison Spilsbury and Trevor Booth for
excellent assistance with confocal imaging and image
co-localization analysis. Post-mortem brain tissue was
obtained from the Newcastle brain tissue resource
(NBTR). We thank the patients and families for their
contributions to this study. Our work was supported by
grants from the UK Medical Research Council (MRC,
G0500247), Newcastle Centre for Brain Ageing and Vital-
ity (BBSRC, EPSRC, ESRC and MRC, LLHW) and Alzhei-
mer’s Research (ARUK). The NBTR is funded by a grant
from the UK MRC (G0400074) with further support from
the Newcastle NIHR Biomedical Research Centre in
Ageing and Age Related Diseases award to the Newcastle
upon Tyne Hospitals NHS Foundation Trust, and a grant
from the Alzheimer’s Society and ART as part of the
Brains for Dementia Research Project.
Author contributions
The individual contributor statements are as follows:
LJLC: Analysis and interpretation of data, acquisition of
the microvascular results and revising the manuscript
at various stages of preparation.
JLT: Analysis and acquisition of the original IHC data in
hereditary stroke disorders.
JYS: Sample preparation, technical assistance and inter-
pretation of immunostaining.
AC: Analysis and additional interpretation of the data.
CH, GK, AB-H and HK: Responsible for clinical and
neuropathological analyses, provision of post-mortem
brain tissue and general advice on analysis.
VD: Assessment of vascular pathological scoring.
A E Oakley: Analysis/interpretation/acquisition of EM
data and technical advice on imaging.
RNK: Drafting, revising the manuscript and interpretation
of data, diagnosing the cases and obtaining funding.
Disclosures
The co-authors have no disclosures with regard to this
report. The study was not industry sponsored. There are
no conflicts of interest.
References
1 He HZ, Song ZM, Wang K, Teng LH, Liu F, Mao YS, Lu N,
Zhang SZ, Wu M, Zhao XH. Alterations in expression,
proteolysis and intracellular localizations of clusterin
in esophageal squamous cell carcinoma. World J
Gastroenterol 2004; 10: 1387–91
2 Nuutinen T, Suuronen T, Kauppinen A, Salminen A.
Clusterin: a forgotten player in Alzheimer’s disease. Brain
Res Rev 2009; 61: 89–104
3 Leskov KS, Klokov DY, Li J, Kinsella TJ, Boothman DA.
Synthesis and functional analyses of nuclear clusterin, a
cell death protein. J Biol Chem 2003; 278: 11590–600
4 Harold D, Abraham R, Hollingworth P, Sims R, Gerrish
A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K,
Williams A, Jones N, Thomas C, Stretton A, Morgan AR,
Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C,
Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K,
Brown KS, Passmore PA, Craig D, McGuinness B, Todd S,
Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Hardy J,
Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F,
Schurmann B, Heun R, van den Bussche H, Heuser I,
Kornhuber J, Wiltfang J, Dichgans M, Frolich L, Hampel
H, Hull M, Rujescu D, Goate AM, Kauwe JS, Cruchaga C,
Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K,
Engelborghs S, De Deyn PP, Van Broeckhoven C,
Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam
R, Deloukas P, Al-Chalabi A, Shaw CE, Tsolaki M,
Singleton AB, Guerreiro R, Muhleisen TW, Nothen MM,
Moebus S, Jockel KH, Klopp N, Wichmann HE,
Carrasquillo MM, Pankratz VS, Younkin SG, Holmans PA,
O’Donovan M, Owen MJ, Williams J. Genome-wide asso-
ciation study identifies variants at CLU and PICALM asso-
ciated with Alzheimer’s disease. Nat Genet 2009; 41:
1088–93
NAN 2016; 42: 194–209
206 L. J. L. Craggs et al.
© 2015 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
on behalf of British Neuropathological Society
5 Lambert JC, Heath S, Even G, Campion D, Sleegers K,
Hiltunen M, Combarros O, Zelenika D, Bullido MJ,
Tavernier B, Letenneur L, Bettens K, Berr C, Pasquier F,
Fievet N, Barberger-Gateau P, Engelborghs S, De Deyn P,
Mateo I, Franck A, Helisalmi S, Porcellini E, Hanon O,
European Alzheimer’s Disease Initiative I, de Pancorbo
MM, Lendon C, Dufouil C, Jaillard C, Leveillard T, Alvarez
V, Bosco P, Mancuso M, Panza F, Nacmias B, Bossu P,
Piccardi P, Annoni G, Seripa D, Galimberti D, Hannequin
D, Licastro F, Soininen H, Ritchie K, Blanche H, Dartigues
JF, Tzourio C, Gut I, Van Broeckhoven C, Alperovitch A,
Lathrop M, Amouyel P. Genome-wide association study
identifies variants at CLU and CR1 associated with Alz-
heimer’s disease. Nat Genet 2009; 41: 1094–9
6 Thambisetty M, Simmons A, Velayudhan L, Hye A,
Campbell J, Zhang Y, Wahlund LO, Westman E, Kinsey A,
Guntert A, Proitsi P, Powell J, Causevic M, Killick R,
Lunnon K, Lynham S, Broadstock M, Choudhry F,
Howlett DR, Williams RJ, Sharp SI, Mitchelmore C,
Tunnard C, Leung R, Foy C, O’Brien D, Breen G, Furney
SJ, Ward M, Kloszewska I, Mecocci P, Soininen H, Tsolaki
M, Vellas B, Hodges A, Murphy DG, Parkins S, Richardson
JC, Resnick SM, Ferrucci L, Wong DF, Zhou Y,
Muehlboeck S, Evans A, Francis PT, Spenger C, Lovestone
S. Association of plasma clusterin concentration with
severity, pathology, and progression in Alzheimer disease.
Arch Gen Psychiatry 2010; 67: 739–48
7 Schrijvers EM, Koudstaal PJ, Hofman A, Breteler MM.
Plasma clusterin and the risk of Alzheimer disease. JAMA
2011; 305: 1322–6
8 Song F, Poljak A, Crawford J, Kochan NA, Wen W,
Cameron B, Lux O, Brodaty H, Mather K, Smythe GA,
Sachdev PS. Plasma apolipoprotein levels are associated
with cognitive status and decline in a community cohort
of older individuals. PLoS ONE 2012; 7: e34078
9 Ijsselstijn L, Dekker LJ, Koudstaal PJ, Hofman A,
Sillevis Smitt PA, Breteler MM, Luider TM. Serum
clusterin levels are not increased in presymptomatic Alz-
heimer’s disease. J Proteome Res 2011; 10: 2006–10
10 Sihlbom C, Davidsson P, Sjogren M, Wahlund LO, Nilsson
CL. Structural and quantitative comparison of cerebro-
spinal fluid glycoproteins in Alzheimer’s disease patients
and healthy individuals. Neurochem Res 2008; 33:
1332–40
11 Desikan RS, Thompson WK, Holland D, Hess CP, Brewer
JB, Zetterberg H, Blennow K, Andreassen OA, McEvoy LK,
Hyman BT, Dale AM, Alzheimer’s Disease Neuroimaging
Initiative G. The role of clusterin in amyloid-beta-
associated neurodegeneration. JAMA Neurol 2014; 71:
180–7
12 Monet-Lepretre M, Haddad I, Baron-Menguy C, Fouillot-
Panchal M, Riani M, Domenga-Denier V, Dussaule C,
Cognat E, Vinh J, Joutel A. Abnormal recruitment of
extracellular matrix proteins by excess Notch3 ECD: a
new pathomechanism in CADASIL. Brain 2013; 136:
1830–45
13 Arboleda-Velasquez JF, Manent J, Lee JH, Tikka S, Ospina
C, Vanderburg CR, Frosch MP, Rodriguez-Falcon M,
Villen J, Gygi S, Lopera F, Kalimo H, Moskowitz MA, Ayata
C, Louvi A, Artavanis-Tsakonas S. Hypomorphic Notch 3
alleles link Notch signaling to ischemic cerebral small-
vessel disease. Proc Natl Acad Sci U S A 2011; 108:
E128–35
14 Kalaria RN, Viitanen M, Kalimo H, Dichgans M, Tabira T,
Vas-Cog CGo. The pathogenesis of CADASIL: an update. J
Neurol Sci 2004; 226: 35–9
15 Takahashi K, Adachi K, Yoshizaki K, Kunimoto S, Kalaria
RN, Watanabe A. Mutations in NOTCH3 cause the for-
mation and retention of aggregates in the endoplasmic
reticulum, leading to impaired cell proliferation.HumMol
Genet 2010; 19: 79–89
16 Yamamoto Y, Craggs LJ, Watanabe A, Booth T, Attems
J, Low RW, Oakley AE, Kalaria RN. Brain microvascular
accumulation and distribution of the NOTCH3
ectodomain and granular osmiophilic material in
CADASIL. J Neuropathol Exp Neurol 2013; 72: 416–
31
17 Carare RO, Hawkes CA, Jeffrey M, Kalaria RN, Weller RO.
Review: cerebral amyloid angiopathy, prion angiopathy,
CADASIL and the spectrum of protein elimination failure
angiopathies (PEFA) in neurodegenerative disease with a
focus on therapy. Neuropathol Appl Neurobiol 2013; 39:
593–611
18 Craggs LJ, Hagel C, Kuhlenbaeumer G, Borjesson-Hanson
A, Andersen O, Viitanen M, Kalimo H, McLean CA, Slade
JY, Hall RA, Oakley AE, Yamamoto Y, Deramecourt V,
Kalaria RN. Quantitative vascular pathology and
phenotyping familial and sporadic cerebral small vessel
diseases. Brain Pathol 2013; 23: 547–57
19 Hachinski V, Iadecola C, Petersen RC, Breteler MM,
Nyenhuis DL, Black SE, Powers WJ, DeCarli C, Merino JG,
Kalaria RN, Vinters HV, Holtzman DM, Rosenberg GA,
Wallin A, Dichgans M, Marler JR, Leblanc GG. National
Institute of Neurological Disorders and Stroke-Canadian
Stroke Network vascular cognitive impairment harmoni-
zation standards. Stroke 2006; 37: 2220–41
20 Sachdev P, Kalaria R, O’Brien J, Skoog I, Alladi S, Black
SE, Blacker D, Blazer DG, Chen C, Chui H, Ganguli M,
Jellinger K, Jeste DV, Pasquier F, Paulsen J, Prins N,
Rockwood K, Roman G, Scheltens P. Diagnostic criteria
for vascular cognitive disorders: a VASCOG statement.
Alzheimer Dis Assoc Disord 2014; 28: 206–18
21 Lewis H, Beher D, Cookson N, Oakley A, Piggott M, Morris
CM, Jaros E, Perry R, Ince P, Kenny RA, Ballard CG,
Shearman MS, Kalaria RN. Quantification of Alzheimer
pathology in ageing and dementia: age-related accumu-
lation of amyloid-beta(42) peptide in vascular dementia.
Neuropathol Appl Neurobiol 2006; 32: 103–18
22 Low WC, Santa Y, Takahashi K, Tabira T, Kalaria RN.
CADASIL-causing mutations do not alter Notch3 recep-
tor processing and activation. Neuroreport 2006; 17:
945–9
NAN 2016; 42: 194–209
Clusterin/Apolipoprotein J immunoreactivity 207
© 2015 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
on behalf of British Neuropathological Society
23 Bolte S, Cordelieres FP. A guided tour into subcellular
colocalization analysis in light microscopy. J Microsc
2006; 224: 213–32
24 Deramecourt V, Slade JY, Oakley AE, Perry RH, Ince PG,
Maurage CA, Kalaria RN. Staging and natural history of
cerebrovascular pathology in dementia. Neurology 2012;
78: 1043–50
25 Lampert-Etchells M, McNeill TH, Laping NJ, Zarow C,
Finch CE, May PC. Sulfated glycoprotein-2 is increased in
rat hippocampus following entorhinal cortex lesioning.
Brain Res 1991; 563: 101–6
26 Pasinetti GM, Johnson SA, Rozovsky I, Lampert-Etchells
M, Morgan DG, Gordon MN, Morgan TE, Willoughby D,
Finch CE. Complement C1qB and C4 mRNAs responses to
lesioning in rat brain. Exp Neurol 1992; 118: 117–25
27 May PC, Clemens JA, Panetta JA, Smalstig EB, Stephenson
D, Fuson KS. Induction of sulfated glycoprotein-2
(clusterin) and glial fibrillary acidic protein (GFAP) RNA
expression following transient global ischemia is differen-
tially attenuated by LY231617. Brain Res Mol Brain Res
1996; 42: 145–8
28 May PC, Finch CE. Sulfated glycoprotein 2: new rela-
tionships of this multifunctional protein to neuro-
degeneration. Trends Neurosci 1992; 15: 391–6
29 Yamashita K, Vogel P, Fritze K, Back T, Hossmann KA,
Wiessner C. Monitoring the temporal and spatial activa-
tion pattern of astrocytes in focal cerebral ischemia using
in situ hybridization to GFAP mRNA: comparison with
sgp-2 and hsp70 mRNA and the effect of glutamate
receptor antagonists. Brain Res 1996; 735: 285–97
30 Van Beek J, Chan P, Bernaudin M, Petit E, MacKenzie ET,
Fontaine M. Glial responses, clusterin, and complement
in permanent focal cerebral ischemia in the mouse. Glia
2000; 31: 39–50
31 Kullberg S, Aldskogius H, Ulfhake B. Microglial activa-
tion, emergence of ED1-expressing cells and clusterin
upregulation in the aging rat CNS, with special reference
to the spinal cord. Brain Res 2001; 899: 169–86
32 Danik M, Chabot JG, Hassan-Gonzalez D, Suh M, Quirion
R. Localization of sulfated glycoprotein-2/clusterin
mRNA in the rat brain by in situ hybridization. J Comp
Neurol 1993; 334: 209–27
33 Giannakopoulos P, Kovari E, French LE, Viard I, Hof PR,
Bouras C. Possible neuroprotective role of clusterin in
Alzheimer’s disease: a quantitative immunocytochemical
study. Acta Neuropathol 1998; 95: 387–94
34 Howlett DR, Hortobagyi T, Francis PT. Clusterin associ-
ates specifically with abeta40 in Alzheimer’s disease
brain tissue. Brain Pathol 2013; 23: 623–32
35 McGeer PL, Kawamata T, Walker DG. Distribution of
clusterin in Alzheimer brain tissue. Brain Res 1992; 579:
337–41
36 Zlokovic BV, Martel CL, Matsubara E, McComb JG, Zheng
G, McCluskey RT, Frangione B, Ghiso J. Glycoprotein
330/megalin: probable role in receptor-mediated trans-
port of apolipoprotein J alone and in a complex with
Alzheimer disease amyloid beta at the blood-brain and
blood-cerebrospinal fluid barriers. Proc Natl Acad Sci U S
A 1996; 93: 4229–34
37 Yu JT, Tan L. The role of clusterin in Alzheimer’s disease:
pathways, pathogenesis, and therapy. Mol Neurobiol
2012; 45: 314–26
38 Trougakos IP, Gonos ES. Clusterin/apolipoprotein J in
human aging and cancer. Int J Biochem Cell Biol 2002;
34: 1430–48
39 Choi-Miura NH, Oda T. Relationship between multifunc-
tional protein ‘clusterin’ and Alzheimer disease.Neurobiol
Aging 1996; 17: 717–22
40 Jokinen H, Schmidt R, Ropele S, Fazekas F, Gouw AA,
Barkhof F, Scheltens P, Madureira S, Verdelho A, Ferro
JM, Wallin A, Poggesi A, Inzitari D, Pantoni L, Erkinjuntti
T, Group LS. Diffusion changes predict cognitive and
functional outcome: the LADIS study. Ann Neurol 2013;
73: 576–83
41 Yang CR, Leskov K, Hosley-Eberlein K, Criswell T, Pink JJ,
Kinsella TJ, Boothman DA. Nuclear clusterin/XIP8, an
x-ray-induced Ku70-binding protein that signals cell
death. Proc Natl Acad Sci U S A 2000; 97: 5907–12
Supporting information
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online version of this article at the publisher’s web-site:
Figure S1. Clusterin immunostaining in axons was
assessed using a modified scoring scale according to the
following scale: 0, no axonal staining (46 year-old male
cognitively normal young control); 1, infrequent, short
punctate staining (81 year-old male cognitively normal
old control); 2, infrequent staining of individual axons (81
year-old female small vessel disease dementia case); 3,
patches of punctate staining with swollen axonal lengths
(48 year-old female Swedish hereditary multi-infarct
dementia); 4, tracts of densely stained and swollen axons
but unstained areas still apparent (96 year-old male
with small vessel disease dementia); 5, complete areas of
densely stained and swollen axons (59 year-old
female with pontine autosomal dominant arteriopathy
microangiopathy and leukoencephalopathy).
Figure S2. Representative immunoblot of protein
extracts from white matter. YC, young control; OC, old
control; 95+, cognitively normal control aged >95 years;
SVD, small vessel disease; CAD, CADASIL; Std, pooled
sample of all cases used as a loading control. Anti-
clusterin antibody detected bands at 38 kDa in all cases, as
well as a second band at 55 kDa in one CADASIL case.
Following detection with clusterin, the membrane was
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stripped and re-probed with anti-α/β Tubulin was used as
a loading control (antibody #2148S, Cell Signalling, Cell
Signaling Technology, Inc., Danvers, MA, United States)
which detected a 55 kDa band in all cases. Molecular
weight marker is identified on the left with protein bands
100, 75, 50, 40, 35, 25 and 15 kDa.
Figure S3. Clusterin was found to stain around pial arter-
ies suggesting clearance of the protein with bound pro-
teins such as amyloid β 1–40 through the perivascular
drainage route. (A) Clusterin (red) and smooth muscle
alpha actin (green) immunostaining within pial vessels
beneath the meninges of 77 year-old female with cerebral
amyloid angiopathy (CAA), Braak stage 6, CERAD fre-
quent (DAPI counterstain). (B) Clusterin (red) and smooth
muscle alpha actin (green) immunostaining within pial
vessel beneath the meninges in CADASIL [61 year-old
male CADASIL case with R169C mutation (DAPI
counterstain)]. (C) Clusterin (green) was found to accu-
mulate around pial vessel walls of arterioles with amyloid
β 1–40 (red), suggesting the bound proteins may be
cleared by the perivascular drainage route, 88 year-old
male with cerebral amyloid angiopathy (CAA), Braak
stage 6, CERAD frequent (no counterstain).
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